source
- Superluminal Medicines raises $60M Series B to launch Phase 1 trial of genetic obesity therapySuperluminal Medicines, a Boston‑based biotech, announced it has closed a $60 million Series B financing round. The capital will fund the company’s first‑in‑human study of its genetic obesity candi…
- Boston Scientific recalls Infinion CX spinal cord stimulator leads over risk of mechanical stress and fractureBoston Scientific issued a recall of its Infinion CX spinal cord stimulator leads after identifying a risk of mechanical stress at the anchor site that can cause high impedance readings or lead fra…